Opendata, web and dolomites

AntiHelix SIGNED

DNA helicases in genome maintenance: from molecular and cellular mechanisms to specific inhibitors as potential drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AntiHelix project word cloud

Explore the words cloud of the AntiHelix project. It provides you a very rough idea of what is the project "AntiHelix" about.

mechanisms    physics    motor    market    techniques    act    companies    recombination    secondments    duplexes    mechanism    academic    drugs    structure    anti    repair    class    eukaryotic    cancer    play    physiological    cellular    antiviral    human    discover    helicases    antibiotic    reproducibility    atp    oncology    biology    tested    enzymes    reaction    protein    viruses    educate    molecule    rna    instrumentation    drug    ubiquitous    coupled    functions    biochemical    private    training    picture    transport    commitment    dna    date    source    action    dimension    competence    science    accessibility    complementary    of    generation    remodel    expertise    job    biophysical    function    structural    full    implicated    chemistry    separate    bacteria    insights    relationships    molecular    variety    cells    single    revealed    experts    found    sectors    obtain    integrity    replication    transparency    therapeutic    diseases    archaea    proteins    diverse    cancers    stage    laboratories    energy    inhibitors    young    translation    genetic    openness    discovery    skills    clinical    culture    scientists    competitive   

Project "AntiHelix" data sheet

The following table provides information about the project.

Coordinator
CONSIGLIO NAZIONALE DELLE RICERCHE 

Organization address
address: PIAZZALE ALDO MORO 7
city: ROMA
postcode: 185
website: www.cnr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 3˙508˙622 €
 EC max contribution 3˙508˙622 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) coordinator 522˙999.00
2    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 595˙044.00
3    ELETTRA - SINCROTRONE TRIESTE SCPA IT (BASOVIZZA TRIESTE) participant 522˙999.00
4    LEAD DISCOVERY CENTER GMBH DE (DORTMUND) participant 505˙576.00
5    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 303˙172.00
6    EDELRIS SAS FR (LYON) participant 274˙802.00
7    LUMICKS B.V. NL (AMSTERDAM) participant 265˙619.00
8    STICHTING VU NL (AMSTERDAM) participant 265˙619.00
9    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 252˙788.00

Map

 Project objective

Helicases are ubiquitous enzymes, found in viruses, Bacteria, Archaea and eukaryotic cells. They act as motor proteins to separate or remodel DNA or RNA duplexes, using ATP as an energy source. Helicases play a key role in a variety of cellular processes, including DNA replication/repair/recombination, as well as RNA translation and transport. They are emerging as an important class of targets for antiviral, antibiotic and anti-cancer drugs. To date, several genetic and biochemical studies have revealed the molecular and physiological functions of DNA helicases. Moreover, protein three-dimension structural studies coupled with single molecule biophysical approaches have provided insights into structure-function relationships and reaction mechanisms of some key DNA helicases. With a consortium including experts with complementary competence and expertise in Physics, Chemistry, Biology and Clinical Oncology, and a strong commitment of companies involved in drug discovery or in the development of state-of-the-art biophysical instrumentation, we aim to: 1. obtain a detailed picture of the mechanism of action and the physiological role of a number of DNA helicases that are implicated in human diseases; 2. discover specific inhibitors of those enzymes, which can then be tested as novel therapeutic drugs, especially for cancers; 3. address the need for training next generation scientists with complementary approaches and diverse techniques by secondments in different laboratories of the consortium; 4. promote a culture of collaboration between academic and private sectors and provide young scientists with the necessary experience and skills to exploit the full potential of research findings; 5. provide early stage researchers with greater opportunities to access an increasingly competitive job market; 6. promote the values of Open Science and educate young scientists on the importance of a culture of openness, transparency, accessibility, integrity and reproducibility.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTIHELIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTIHELIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

HEARTLAND (2019)

Health, Environment, Agriculture, Rural development: Training network for LAND management

Read More  

ENHAnCE (2020)

European training Network in intelligent prognostics and Health mAnagement in Composite structurEs

Read More  

HeatNMof (2020)

Heating triggered drug release from nanometric inorganic-metal organic framework composites

Read More